Opinion|Videos|August 2, 2024
AE Management for CAR-T Therapy: Expert Insights and Perspectives
Samer Al'Hadidi, MD, provides a comprehensive overview of adverse event management practices for patients with multiple myeloma who receive CAR T-cell therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Please discuss AE management practices for CAR T-cell therapy.
- What are some adverse events seen with ide-cel and cilta-cel?
- Review some strategies to help manage AEs.
- How do they compare with bispecifics?
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
2
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
3
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
4
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?
5